Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: CRK

Gene summary for CRK

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

CRK

Gene ID

1398

Gene nameCRK proto-oncogene, adaptor protein
Gene AliasCRKII
Cytomap17p13.3
Gene Typeprotein-coding
GO ID

GO:0000302

UniProtAcc

A0A0S2Z3K9


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
1398CRKHTA11_3410_2000001011HumanColorectumAD2.52e-02-1.71e-010.0155
1398CRKHTA11_347_2000001011HumanColorectumAD5.62e-115.00e-01-0.1954
1398CRKHTA11_411_2000001011HumanColorectumSER8.31e-058.78e-01-0.2602
1398CRKHTA11_83_2000001011HumanColorectumSER4.62e-024.63e-01-0.1526
1398CRKHTA11_1391_2000001011HumanColorectumAD1.13e-056.12e-01-0.059
1398CRKHTA11_99999971662_82457HumanColorectumMSS2.79e-02-1.96e-010.3859
1398CRKA002-C-010HumanColorectumFAP2.08e-02-2.13e-010.242
1398CRKA001-C-207HumanColorectumFAP1.95e-04-3.53e-010.1278
1398CRKA015-C-203HumanColorectumFAP1.71e-22-3.60e-01-0.1294
1398CRKA015-C-204HumanColorectumFAP7.64e-04-2.70e-01-0.0228
1398CRKA014-C-040HumanColorectumFAP2.14e-02-4.20e-01-0.1184
1398CRKA002-C-201HumanColorectumFAP1.76e-06-2.31e-010.0324
1398CRKA001-C-119HumanColorectumFAP8.38e-04-3.59e-01-0.1557
1398CRKA001-C-108HumanColorectumFAP1.18e-12-3.04e-01-0.0272
1398CRKA002-C-205HumanColorectumFAP2.60e-13-3.06e-01-0.1236
1398CRKA001-C-104HumanColorectumFAP5.59e-03-2.08e-010.0184
1398CRKA015-C-005HumanColorectumFAP2.05e-05-3.24e-01-0.0336
1398CRKA015-C-006HumanColorectumFAP4.68e-10-4.21e-01-0.0994
1398CRKA015-C-106HumanColorectumFAP8.27e-09-1.98e-01-0.0511
1398CRKA002-C-114HumanColorectumFAP5.30e-10-2.53e-01-0.1561
Page: 1 2 3 4 5 6 7 8 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0007163111ThyroidPTCestablishment or maintenance of cell polarity115/5968218/187231.15e-103.90e-09115
GO:000726519ThyroidPTCRas protein signal transduction162/5968337/187233.16e-101.02e-08162
GO:0008360111ThyroidPTCregulation of cell shape86/5968154/187236.22e-101.95e-0886
GO:007156019ThyroidPTCcellular response to transforming growth factor beta stimulus126/5968250/187237.34e-102.19e-08126
GO:1901653111ThyroidPTCcellular response to peptide169/5968359/187239.81e-102.89e-08169
GO:0043393111ThyroidPTCregulation of protein binding103/5968196/187231.39e-093.96e-08103
GO:0010810112ThyroidPTCregulation of cell-substrate adhesion113/5968221/187231.87e-095.28e-08113
GO:0031589111ThyroidPTCcell-substrate adhesion169/5968363/187232.73e-097.57e-08169
GO:0043434113ThyroidPTCresponse to peptide hormone188/5968414/187234.13e-091.09e-07188
GO:0042060112ThyroidPTCwound healing190/5968422/187237.72e-091.92e-07190
GO:0010769111ThyroidPTCregulation of cell morphogenesis involved in differentiation57/596896/187232.50e-085.62e-0757
GO:0071375110ThyroidPTCcellular response to peptide hormone stimulus136/5968290/187235.49e-081.17e-06136
GO:0010975110ThyroidPTCregulation of neuron projection development194/5968445/187231.05e-072.08e-06194
GO:001072018ThyroidPTCpositive regulation of cell development138/5968298/187231.13e-072.22e-06138
GO:0010770111ThyroidPTCpositive regulation of cell morphogenesis involved in differentiation48/596879/187231.15e-072.26e-0648
GO:001635819ThyroidPTCdendrite development115/5968243/187233.16e-075.35e-06115
GO:003001020ThyroidPTCestablishment of cell polarity74/5968143/187236.05e-079.63e-0674
GO:0010811112ThyroidPTCpositive regulation of cell-substrate adhesion65/5968123/187231.10e-061.62e-0565
GO:0034446111ThyroidPTCsubstrate adhesion-dependent cell spreading58/5968108/187232.07e-062.82e-0558
GO:1900024111ThyroidPTCregulation of substrate adhesion-dependent cell spreading35/596857/187234.20e-065.20e-0535
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa05131ColorectumADShigellosis109/2092247/84651.09e-112.44e-101.55e-10109
hsa05100ColorectumADBacterial invasion of epithelial cells44/209277/84651.13e-092.22e-081.42e-0844
hsa04666ColorectumADFc gamma R-mediated phagocytosis46/209297/84659.10e-071.22e-057.77e-0646
hsa05135ColorectumADYersinia infection58/2092137/84653.90e-064.35e-052.78e-0558
hsa04722ColorectumADNeurotrophin signaling pathway50/2092119/84652.28e-052.24e-041.43e-0450
hsa05170ColorectumADHuman immunodeficiency virus 1 infection72/2092212/84651.40e-038.46e-035.39e-0372
hsa05220ColorectumADChronic myeloid leukemia31/209276/84651.41e-038.46e-035.39e-0331
hsa04015ColorectumADRap1 signaling pathway71/2092210/84651.72e-039.68e-036.18e-0371
hsa05163ColorectumADHuman cytomegalovirus infection75/2092225/84652.00e-031.10e-027.01e-0375
hsa05211ColorectumADRenal cell carcinoma28/209269/84652.58e-031.37e-028.75e-0328
hsa04810ColorectumADRegulation of actin cytoskeleton75/2092229/84653.36e-031.76e-021.12e-0275
hsa04510ColorectumADFocal adhesion67/2092203/84654.40e-032.17e-021.38e-0267
hsa04012ColorectumADErbB signaling pathway31/209285/84651.02e-023.91e-022.50e-0231
hsa051311ColorectumADShigellosis109/2092247/84651.09e-112.44e-101.55e-10109
hsa051001ColorectumADBacterial invasion of epithelial cells44/209277/84651.13e-092.22e-081.42e-0844
hsa046661ColorectumADFc gamma R-mediated phagocytosis46/209297/84659.10e-071.22e-057.77e-0646
hsa051351ColorectumADYersinia infection58/2092137/84653.90e-064.35e-052.78e-0558
hsa047221ColorectumADNeurotrophin signaling pathway50/2092119/84652.28e-052.24e-041.43e-0450
hsa051701ColorectumADHuman immunodeficiency virus 1 infection72/2092212/84651.40e-038.46e-035.39e-0372
hsa052201ColorectumADChronic myeloid leukemia31/209276/84651.41e-038.46e-035.39e-0331
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
CRKSNVMissense_Mutationnovelc.608N>Ap.Gly203Aspp.G203DP46108protein_codingdeleterious(0.03)benign(0.006)TCGA-BH-A0HF-01Breastbreast invasive carcinomaFemale>=65I/IIHormone TherapyarimidexSD
CRKSNVMissense_Mutationnovelc.777G>Tp.Glu259Aspp.E259DP46108protein_codingtolerated(0.07)benign(0.118)TCGA-AJ-A8CW-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
CRKSNVMissense_Mutationrs145983279c.562G>Ap.Glu188Lysp.E188KP46108protein_codingdeleterious(0.02)benign(0.438)TCGA-AX-A06F-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinSD
CRKSNVMissense_Mutationnovelc.795N>Tp.Lys265Asnp.K265NP46108protein_codingdeleterious(0.02)probably_damaging(0.955)TCGA-AX-A1CE-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnspecificPaclitaxelSD
CRKSNVMissense_Mutationrs748897674c.686N>Tp.Pro229Leup.P229LP46108protein_codingdeleterious(0.02)benign(0.157)TCGA-D1-A16R-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
CRKSNVMissense_Mutationnovelc.385N>Ap.Leu129Ilep.L129IP46108protein_codingtolerated(0.23)benign(0)TCGA-E6-A1M0-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinSD
CRKSNVMissense_Mutationnovelc.721N>Gp.Arg241Glyp.R241GP46108protein_codingdeleterious(0)probably_damaging(0.95)TCGA-FI-A2F4-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
CRKdeletionFrame_Shift_Delc.818delNp.Gly273ValfsTer66p.G273Vfs*66P46108protein_codingTCGA-55-7725-01Lunglung adenocarcinomaFemale>=65I/IIUnknownUnknownSD
CRKSNVMissense_Mutationrs776920144c.559N>Ap.Val187Ilep.V187IP46108protein_codingtolerated(0.09)possibly_damaging(0.63)TCGA-CN-5365-01Oral cavityhead & neck squamous cell carcinomaMale<65I/IIUnknownUnknownPD
CRKSNVMissense_Mutationc.172N>Gp.Ser58Alap.S58AP46108protein_codingdeleterious(0.01)probably_damaging(0.998)TCGA-CH-5748-01Prostateprostate adenocarcinomaMale<657UnknownUnknownSD
Page: 1 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1